Theoretical and Natural Science
- The Open Access Proceedings Series for Conferences
Theoretical and Natural Science
Vol. 21, 20 December 2023
Open
Access | Article
Albumin-binding prodrugs’ use in treating cancer
* Author to whom correspondence should be addressed.
Abstract
Throughout the past few decades, the use of targeted delivery methods for cancer therapies has dramatically increased. Prodrug, a type of drug that can apply the targeting therapy, is defined as chemicals that undergo chemical transformations after enters the patient’s body. They will be activated and release the parent drug after reached the targeted site. Both passively and actively targeted therapies are explored. The albumin-binding prodrug, a model of prodrug applying passively targeted therapy, this paper introduces the enhanced permeability and retention (EPR) effect to target the tumor site. Besides, since the human serum albumin is an endogenous substance originated from human body, its nanoparticles is able to carry the anticancer drugs to elongate the circulatory half-lives of drugs since it will not be rejected by the immune system. However, the activated compound's systemic toxicity and the dearth of information regarding the biodistribution of prodrugs are two possible disadvantages. Moreover, some exogenous albumin formulations are prohibited from participating in clinical trials because of their very poor delivery efficiency. In conclusion, the albumin-binding prodrug is a cancer treating therapy that has great promise and great capability despite the potential risks.
Keywords
albumin-binding prodrugs, anticancer, the EPR effect
References
1. Daniel Rosenblum, Nitin Joshi, Wei Tao, Jeffery M. Karp and Dan Peer, Progress and challenges towards targeted delivery of cancer therapeutics, April 12 (2018).
2. Hanhee Cho, Seong Ik Jeon, Chole-Hee Ahn, Man Kyu Shim, and Kwangmeyung Kim, Emerging Albumin-Binding Anticancer Drugs for Tumor-Targeted Drug Delivery: Current Understandings and Clinical Translation, March 28 (2022).
3. Irene Giang, Erin L. Boland, and Gregory M.K. Poon, Prodrug Applications for Targeted Cancer Therapy. July 9, Rev. 16(5): 899–913 (2014).
4. Patel, B.S. Pattni, A.H. Abouzeid, V.P. Torchilin, Nanopreparations to overcome multidrug resistance in cancer, Adv. Drug Delivery Rev. 65, pp.1748-1762 (2013).
5. J. Rautio, H. Kumpulainen, T. Heimbach, R. Oliyai, D. Oh, T. Jarvinen, J. Savolainen, Prodrugs: design and clinical applications, Nat Rev Drug Discov 7, pp.255-270 (2008).
6. J.B. Zawilska, J. Wojcieszak, A.B. Olejniczak, Prodrugs: a challenge for the drug development, Pharmacol. Rep. 65, pp.1-14 (2013).
7. K.M. Huttunen, H. Raunio, J. Rautio, Prodrugs-from serendipity to rational design, Pharmacol. Rev. 63, pp.750-771 (2011).
8. Wooram Um, Jooho Park et al, A Comparative Study on Albumin-Binding Molecules for Targeted Tumor Delivery through Covalent and Noncovalent Approach. November 22, 2019 Bioconjugate Chem, 30, 3107−3118 (2019).
9. Maria V. Liberty, Jason W. Locasale, The Warburg Effect: How Does it Benefit Cancer Cells? Jan 5 (2016).
10. Islam Hassanin, Ahmed Elzoghby, Albumin-based nanoparticles: a promising strategy to overcome cancer drug resistance. October 9 (2020).
11. James D. Byrne a, Tania Betancourt b, Lisa Brannon-Peppas, Active targeting schemes for nanoparticle systems in cancer therapeutics. December 14 (2008).
12. Frei E. Albumin binding ligands and albumin conjugate uptake by cancer cells. Diabetol. Metab. Syndr (2011).
13. Tianmeng Sun, Yu Zhang et al, Engineered nanoparticles for drug delivery in cancer therapy. November 10, (2014).
14. Zhao P., Wang Y., Wu A., Rao Y., Huang Y., Roles of Albumin-Binding Proteins in Cancer Progression and Biomimetic Targeted Drug Delivery, ChemBioChem (2018).
15. Kevin Le, PharmD, BCPS, BCPPS. What Is a Prodrug? How Prodrugs Work, Examples, and More. October 25 (2021).
Data Availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).
- Volume Title
- Proceedings of the 3rd International Conference on Biological Engineering and Medical Science
- ISBN (Print)
- 978-1-83558-215-2
- ISBN (Online)
- 978-1-83558-216-9
- Published Date
- 20 December 2023
- Series
- Theoretical and Natural Science
- ISSN (Print)
- 2753-8818
- ISSN (Online)
- 2753-8826
- DOI
- 10.54254/2753-8818/21/20230826
- Copyright
- 20 December 2023
- Open Access
- This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited